Abstract
Background Cystic fibrosis (CF) research increasingly focuses on the extra-pulmonary manifestations of CF. including its effects on the gastrointestinal (GI) system and was identify as a research priority by the CF community. However, evidence gaps in understanding GI pathology in CF remain, which is in part due to inconsistencies in outcome reporting in GI research in CF. This rapid review aims to identify and describe the range of outcome measurement instruments (OMIs) and associated endpoints currently used in CF GI research. Methods This PROSPERO-registered review (CRD42021281961) followed Cochrane Rapid Reviews Methods Group guidance. Comprehensive searches were performed in MEDLINE, EMBASE, PubMed, Cochrane Library, and ongoing clinical trials databases, over an 11-year period (August 2013 to November 2024). Screening and data extraction were conducted using Covidence online software. Results A total of 1,541 articles were identified, of which 193 met inclusion criteria. These articles collectively used 246 distinct OMIs, of which 172 (70%) were used only once. OMIs were grouped into 14 sub-domains of CF GI research and then mapped to 11 of the 38 COMET taxonomy domains. Outcomes reflected a diverse range of mechanistic and patient-centred measures, reflecting the complexity of GI disease in CF. Conclusions GI research in CF uses a heterogeneous array of OMIs, highlighting the variability and potential inefficiency in current outcome reporting practices. Development of a core outcome set could help to promote consistency in outcome reporting, enhancing study comparability and help to address CF research priorities.
Competing Interest Statement
AY reports grants to support work from Vertex Pharmaceuticals RC reports work supported from an NIHR programme development grant JH, HB, RM and SS have nothing to disclose KM reports grants from NIHR paid to their institution AS reports that he has been part of an advisory board from Viatris Pharmaceuticals and has received research grants from Vertex Pharmaceuticals (both outside this current work). He holds a patent issued Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/view/CRD42021281961
Funding Statement
NIHR Programme Development Grant reference NIHRPDG202952
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The dataset supporting the conclusions of this article is available upon reasonable request to the study chief investigator Prof Alan Smyth. Alan.smyth@qub.ac.uk.
